LOS ANGELES/PRNewswire/ — Grifols, a global healthcare
company and biopharmaceutical manufacturer based in Barcelona, Spain, announced
that its U.S. diagnostic and hospital divisions have received ISO
13485:2003+AC:2009 certification, an international quality standard that sets
forth voluntary benchmarks for the design, manufacture and distribution of
medical devices.
Grifols is the third largest global producer of medicines
derived from human plasma and a manufacturer of diagnostic tools, hospital
products and medical devices. ISO 3485:2003+AC:2009 certification demonstrates
a company’s adherence to a quality management system that administers and
oversees a wide range of safety, compliance and regulatory standards related to
medical devices.
Grifols’ medical devices are produced in Barcelona,
Spain and are distributed in
the U.S. through its Miami location.
About Grifols
Grifols is a global pharmaceutical company develops and produces plasma-derived
therapies and manufactures hospital pharmacy products, intravenous solutions,
diagnostic tools and medical devices. As the third largest global producer of
plasma therapies, Grifols has a presence in more than 90 countries and is the
world leader in plasma collection, with 147 plasma donation centers across the U.S. The
company’s class A shares have been listed on the Spanish Stock Exchange since 2006 and have been part of the Ibex-35 since 2008. In 2011, the
company listed non-voting class B shares on the Mercado Continuo (MCE:GRF.P)
and on the U.S. NASDAQ via ADRs.
About ISO
The International Organization for Standardization (ISO) is the world’s largest
developer and publisher of international standards that apply to business,
government and society. ISO is a network of the national standards institutes
of 163 countries, with a central secretariat in Geneva, Switzerland
that coordinates the system. ISO is a non-governmental organization that forms
a bridge between the public and private sectors and enables consensus to be
reached on solutions that meet the requirements of businesses and the broader
needs of society.
Posted by Sean Fenske, Editor-in-Chief, MDT
